Related Experiment Video
Updated: Aug 22, 2025

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Cryptococcal Pneumonia in an Immunocompetent Patient: A Rare Occurrence.
Muhammad S Haider1, Madiha Master2, Arun Mahtani1
1Internal Medicine, Richmond University Medical Center, New York, USA.
This case study highlights a rare instance of cryptococcal pneumonia in an immunocompetent 69-year-old male. Early diagnosis and antifungal treatment with fluconazole improved symptoms before chemotherapy for concurrent lung adenocarcinoma.
Area of Science:
- Infectious Diseases
- Pulmonology
- Oncology
Background:
- Cryptococcosis is an invasive fungal infection typically seen in immunocompromised individuals.
- Pulmonary cryptococcosis presents with varied radiographic findings and symptoms mimicking bacterial pneumonia.
- Diagnosis involves fungal cultures, histology, and cryptococcal antigen testing.
Observation:
- A 69-year-old immunocompetent male presented with persistent respiratory symptoms initially treated as pneumonia.
- CT scans revealed infiltrates and consolidations, and bronchoscopy identified lung adenocarcinoma.
- Fungal cultures confirmed *Cryptococcus neoformans* infection.
Findings:
- The patient received fluconazole for cryptococcal pneumonia, showing symptom improvement.
- The case involved a dual diagnosis of cryptococcal pneumonia and lung adenocarcinoma in an immunocompetent host.
- This presentation is unusual, as cryptococcosis predominantly affects immunocompromised patients.
Implications:
- This case underscores the importance of considering fungal etiologies in persistent pneumonia, even in immunocompetent patients.
- It highlights the diagnostic challenge when fungal infections co-exist with malignancies.
- Early recognition and treatment of cryptococcosis are crucial for patient outcomes, especially when underlying conditions like cancer are present.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pneumonia III: Complications and Assessment
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology

